What The Budget Bill Has In Store For Medical Cos.

Law360 (January 10, 2020, 2:33 PM EST) -- On Dec. 20, 2019, President Donald Trump signed into law an appropriations bill containing a number of provisions that will significantly impact the health care industry and life sciences companies.

Among other things, this law repeals certain taxes imposed by the Affordable Care Act; requires innovator pharmaceutical companies to make samples of their drugs available to eligible product developers who request them; adds chemically synthesized polypeptides to the category of biologics regulated by the U.S. Food and Drug Administration; and provides additional funding for research on diseases including cancer and Alzheimer’s.

Noticeably absent from the bill are controversial proposals governing drug pricing...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS